5HU Stock Overview
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Hemogenyx Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.011 |
| 52 Week High | UK£0.052 |
| 52 Week Low | UK£0.0075 |
| Beta | 3.05 |
| 1 Month Change | -4.17% |
| 3 Month Change | -60.34% |
| 1 Year Change | -39.47% |
| 3 Year Change | -39.47% |
| 5 Year Change | n/a |
| Change since IPO | -86.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | 1.9% |
| 1Y | -39.5% | -25.4% | 5.9% |
Return vs Industry: 5HU underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 5HU underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 5HU volatility | |
|---|---|
| 5HU Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HU's share price has been volatile over the past 3 months.
Volatility Over Time: 5HU's weekly volatility has decreased from 19% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 14 | Vladislav Sandler | www.hemogenyx.com |
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Hemogenyx Pharmaceuticals Plc Fundamentals Summary
| 5HU fundamental statistics | |
|---|---|
| Market cap | €24.91m |
| Earnings (TTM) | -€7.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs 5HU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HU income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£6.69m |
| Earnings | -UK£6.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.005 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5HU perform over the long term?
See historical performance and comparison